AtaiBeckley (ATAI) Other Operating Expenses (2020 - 2023)

AtaiBeckley (ATAI) posted Other Operating Expenses of $60.2 million for Q4 2023, up 236.78% sequentially from $17.9 million in Q4 2021.

AtaiBeckley (ATAI) Other Operating Expenses (2020 - 2023) Analysis & Trends

AtaiBeckley has reported Other Operating Expenses for 3 years, with the latest figure at $60.2 million in Q4 2023.

Quarterly Other Operating Expenses changed N/A year-over-year to $60.2 million in Q4 2023, while the trailing twelve-month figure through Sep 2024 was $60.2 million (changed N/A YoY) and the FY2023 annual result came in at $60.2 million, changed N/A from the prior year.
Other Operating Expenses improved to $60.2 million in Q4 2023 per ATAI's latest filing, from $17.9 million in the prior quarter.
Over five years, Other Operating Expenses peaked at $60.2 million in Q4 2023 and troughed at -$5.5 million in Q2 2021.
A 3-year average of $12.2 million and a median of $972000.0 in 2021 frame the typical range for Other Operating Expenses.
The widest YoY moves for Other Operating Expenses: up 50.22% in 2021, down 4650.0% in 2021.
Over 3 years, Other Operating Expenses stood at $11.9 million in 2020, then surged by 50.22% to $17.9 million in 2021, then jumped by 236.78% to $60.2 million in 2023.
According to Business Quant data, Other Operating Expenses over the past three periods registered $60.2 million, $17.9 million, and -$70000.0 for Q4 2023, Q4 2021, and Q3 2021 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	AtaiBeckley	2.69 Bn	2.69 Bn	-

Download Data